Vaxil Bio Ltd's stock has taken a significant hit, dropping over 16% in just one day.
In the latest trading session, Vaxil Bio Ltd (VXL.V) saw its stock price decline by an alarming 16.22%, closing at CA$0.15. This sharp drop raises concerns for investors about the company's current standing and future prospects.
Investor takeaway: Investors should be cautious as Vaxil Bio Ltd faces substantial volatility, with no recent news to explain the sudden decline.
Advertisement
Get up to $2,000 cash back
Open and fund a new Qtrade account with promo code SPRING26. Offer ends July 31, 2026.
Vaxil Bio Ltd
VXL.V
VXL.V
Vaxil Bio Ltd
WealthAwesomeMarket cap
$617,523
P/E
0.9x
52W high
$0.29
52W low
$0.13
1W change
-13.89%
Beta
-0.89
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on VXL's historical volatility
30-Day Vol
73.1%
Annualized
90-Day Vol
107.9%
Annualized
Trend (90d)
+13.8%
Annualized drift
90d Mean
C$0.16
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$0.16 | C$0.12 – C$0.20 |
| 60 trading days | C$0.16 | C$0.11 – C$0.23 |
| 90 trading days | C$0.16 | C$0.11 – C$0.25 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Vaxil Bio Ltd down 16.22% in one day.
With a market cap of just CA$617,523, Vaxil remains a high-risk investment, especially given its current financial metrics.
Bull case
If Vaxil can successfully leverage its recent private placement and tackle its operational challenges, there could be a chance for recovery.
Bear case
The lack of recent positive news and the company's low market cap suggest that Vaxil may struggle to regain investor confidence, especially considering its history of operational setbacks.
The Decline Explained
Vaxil Bio Ltd's stock has seen a dramatic decrease, dropping 16.22% in just one day. Investors are left questioning the stability of the company, especially given the absence of any recent news or announcements that could have triggered such a sell-off. The company's market cap of CA$617,523 raises further concerns about its viability in the competitive biotech sector.
Looking Ahead
As Vaxil navigates its current challenges, investors should keep a close eye on any developments, particularly regarding its recent private placement and operational updates. The potential for recovery exists, but it heavily depends on the company's ability to restore investor confidence and effectively execute its strategic plans.
Advertisement
